Lavakumar Karyampudi, PhD, Moffitt Cancer Center, Tampa, FL, discusses key challenges and bottlenecks associated with the development of novel cell therapies. Shortening manufacturing times is a priority for producers, where an increased turnaround of therapies will benefit patients. In the field of genetically edited T-cell products that utilize viral vectors, there is an increased demand for contract development and manufacturing company (CDMO) to manufacture the viral vectors. This interview took place at Advanced Therapies Week 2022.
Lavakumar Karyampud, PhD, is an employee of Moffitt Cancer Center.